Effect of Inactivation Methods on SARS-CoV-2 Virion Protein and Structure.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
26 03 2021
Historique:
received: 09 03 2021
accepted: 22 03 2021
entrez: 3 4 2021
pubmed: 4 4 2021
medline: 17 4 2021
Statut: epublish

Résumé

The risk posed by Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2) dictates that live-virus research is conducted in a biosafety level 3 (BSL3) facility. Working with SARS-CoV-2 at lower biosafety levels can expedite research yet requires the virus to be fully inactivated. In this study, we validated and compared two protocols for inactivating SARS-CoV-2: heat treatment and ultraviolet irradiation. The two methods were optimized to render the virus completely incapable of infection while limiting the destructive effects of inactivation. We observed that 15 min of incubation at 65 °C completely inactivates high titer viral stocks. Complete inactivation was also achieved with minimal amounts of UV power (70,000 µJ/cm

Identifiants

pubmed: 33810401
pii: v13040562
doi: 10.3390/v13040562
pmc: PMC8066162
pii:
doi:

Substances chimiques

Viral Proteins 0

Types de publication

Evaluation Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

J Virol Methods. 2021 Apr;290:114087
pubmed: 33515663
Virus Res. 2020 Aug;285:197988
pubmed: 32380210
Curr Med Sci. 2020 Aug;40(4):614-617
pubmed: 32767258
Methods Mol Biol. 2008;454:119-26
pubmed: 19057880
Viruses. 2020 Jun 06;12(6):
pubmed: 32517266
J Virol. 2006 Aug;80(16):7918-28
pubmed: 16873249
J Clin Lab Anal. 2021 Apr;35(4):e23735
pubmed: 33608968
Viruses. 2020 Jul 07;12(7):
pubmed: 32646015
Vet Microbiol. 1990 Jan;21(3):263-73
pubmed: 2154877
J Virol Methods. 2004 Oct;121(1):85-91
pubmed: 15350737
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Nature. 1955 Feb 19;175(4451):352
pubmed: 13235900
Rev Med Virol. 2020 Sep;30(5):e2115
pubmed: 32614102
Am J Infect Control. 2020 Oct;48(10):1273-1275
pubmed: 32763344

Auteurs

Emma K Loveday (EK)

Department of Chemical & Biological Engineering, Montana State University, Bozeman, MT 59717, USA.

Kyle S Hain (KS)

Department of Microbiology & Immunology, Montana State University, Bozeman, MT 59717, USA.

Irina Kochetkova (I)

Department of Microbiology & Immunology, Montana State University, Bozeman, MT 59717, USA.

Jodi F Hedges (JF)

Department of Microbiology & Immunology, Montana State University, Bozeman, MT 59717, USA.

Amanda Robison (A)

Department of Microbiology & Immunology, Montana State University, Bozeman, MT 59717, USA.

Deann T Snyder (DT)

Department of Microbiology & Immunology, Montana State University, Bozeman, MT 59717, USA.

Susan K Brumfield (SK)

Department of Plant Science and Plant Pathology, Montana State University; Bozeman, MT 59717, USA.

Mark J Young (MJ)

Department of Plant Science and Plant Pathology, Montana State University; Bozeman, MT 59717, USA.

Mark A Jutila (MA)

Department of Microbiology & Immunology, Montana State University, Bozeman, MT 59717, USA.

Connie B Chang (CB)

Department of Chemical & Biological Engineering, Montana State University, Bozeman, MT 59717, USA.

Matthew P Taylor (MP)

Department of Microbiology & Immunology, Montana State University, Bozeman, MT 59717, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH